I just Post What I Find!
No Need to Thank Me!
Most of us Know what a Gem this is Going to Be!
Just Takes Time to Make it into a Diamond...
Geode Capital Management LLC Buys 2,363 Shares of TrovaGene Inc (TROV)
July 1st, 2016 - 0 comments - Filed Under - by Mark Dietrich
TrovaGene logoGeode Capital Management LLC increased its stake in TrovaGene Inc (NASDAQ:TROV) by 1.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 183,442 shares of the company’s stock after buying an additional 2,363 shares during the period. Geode Capital Management LLC owned 0.62% of TrovaGene worth $853,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of TROV. State Street Corp raised its position in TrovaGene by 21.3% in the first quarter. State Street Corp now owns 390,759 shares of the company’s stock valued at $1,819,000 after buying an additional 68,557 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in TrovaGene by 6.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 660,640 shares of the company’s stock valued at $3,072,000 after buying an additional 40,100 shares in the last quarter. Prospera Financial Services Inc raised its position in TrovaGene by 3.8% in the first quarter. Prospera Financial Services Inc now owns 158,125 shares of the company’s stock valued at $735,000 after buying an additional 5,800 shares in the last quarter. Finally, First Eagle Investment Management LLC bought a new position in TrovaGene during the fourth quarter valued at about $2,031,000.
I'm Sure Many are on the Way!
This will be a Slow Crawl Climb Up!
But, does it Deserve to be Under $10?
Bet William Patalon is Accumulating Here!
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
6/15/2016 4,478,552 370,020 12.103540
5/31/2016 4,625,048 486,790 9.501115
Short Interest is Dropping!
Yikes! 12 Days to Cover!
Best News All Weekend!
50 mins ·
Earlier this month at #ASCO16, Dr. Heather Wakelee presented an abstract that included our urine-based liquid biopsy test, Trovera, which brought new insights to the liquid biopsy field. Missed the session? Find out from our VP of Research Development, Vlada Melnikova, why this data is so important!
Highly Respect Stock Guru!
His Picks are Early and 80% Accurate!
Bill Patalon thinks $50 is doable for TROV!
Smile and be Happy!
Now we have James Altucher and William Patalon Onboard TROV Train!
Nasdaq: TROV), biotech-sector executive Tina Nova wrote in a Wired magazine essay that the still-in-development cancer-screening technology is "the most exciting thing I've seen since I started my career."